Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The presentation just started.
Oramed will be giving a presentation at Canaccord today @ 4:30 PM Eastern time. Here is the link: https://wsw.com/webcast/canaccord76/ormp/2487690
I recently read this post on the, "No More Excuses! ALS Watch Dog Group":
Dr. Fiona Wood is working on a scar-less wound healing cream.
https://www.uwa.edu.au/news/Article/2022/May/Volunteers-needed-to-trial-scar-less-wound-healing-cream
I wonder why this is not part of Avita Medical.
Just noticed that the Aussie stop jumped up over 21% so far tonight. Any new news out to justify that?
We are owed $450s.
;)
I wish that their covid pill was already out. Just found out I've got it.
Covid blows.
Go up to $496 please.
Lot of range today. Down to a low of $7.44 and then clawing up to $9.16 by the closing bell. I wonder if the stock price can fight it's way back to $11 range or higher by Friday.
My stake is currently 139% in green territory.
I'm taking this to the end of the line.
Either the FDA approves it and I become rich or the FDA screws everyone and I lose some money. It still feels like a safe bet to me.
Just a reminder:
Damn! At this rate, we will pass 48% in minutes instead of the ending bell.
;)
I wouldn't mind seeing another 48% rally today!
;)
If that happens, I'd end up with a substantial 8-digit bank account.
;)
Are you referring to Twitter?
You misunderstand...I already bought in @ $3.50...Now, I'm waiting for the stock to reach a few hundred dollars per share.
;)
My plan was buy @ $3.50 and then sell in the hundreds. ;)
Great pop to the stock over the last three days....up $2.20 so far!
Oramed recently posted these to their Youtube page two days ago:
So, here's the order of the upcoming news:
Phase 2 NASH Data:
(Q3) July, August, or September
The NASH market is projected to reach $84 billion market by 2029.
Oravax:
Cohort A - (Q3) July, August, or September
Cohort B - (Q4) October, November, and December
The vaccine market is projected to reach $125 billion by 2028.
Phase 3 Oral Insulin Trials:
January 2023
Type 2 Diabetes market is projected to reach $92 billion by 2029.
84+125+92 = $301 billion in addressable markets
I would shocked if the stock price did not claw its way back up to the $30 range or higher by New Years Eve.
I wonder if the recent strong bumps to the stock price have something to do with the upcoming news from Nadav about their human covid pill trial? If it's good news, this will increase the odds and confidence that the same tech is also working in their phase 3 insulin trials.
I just read this summary from the investor briefing:
Just read this on the No More Excuses Facebook page:
Roberto wanted everyone to know how #NurOwn made him feel & function just 12 days after his EAP injection.#LivingProof pic.twitter.com/oGPcoVmoyd
— Shelly Goettl (@GoettlShelly) May 31, 2022
Just a reminder that Nadav's presentation from India starts in 8 minutes.
https://us06web.zoom.us/webinar/register/WN_ah9SwP0RTVGlGRhPR26Asw
Didn't the chart say US oral insulin can come to market - early 2024?
Nadav mentioned that by the end of June, he will share where the phase 1 covid trial is currently at. He mentioned that recruitment was slower than anticipated due to a high level of screening failures of potential subjects (many didn't realize that they had covid or HIV, etc). Because of that, Oramed had to go through a lot more volunteers before they had enough subjects that could be randomized for the trial. They will also be testing Oravax as a booster.
Oops, I meant next Wednesday @ 11am central time...my bad.
Oramed's presentation starts @ 11am central time today if anyone wants to watch.
https://journey.ct.events/view/38feb6c2-b0ba-411e-916c-8f5ed39b019e
Aegis Capital Adjusts Price Target for Oramed Pharmaceuticals to $30 From $35, Maintains Buy Rating
Just read this from the Hot Copper forums:
NASDAQ: ORMP Check out this interview with Nadav Kidron, CEO, Oramed Pharmaceuticals Inc., discussing major news about the flagship $ORMP product, an oral #insulin capsule that is currently in advanced clinical trials under the US FDA for type 1 & type 2 diabetes.#ad #pharma pic.twitter.com/gwx6ahsrkO
— Benzinga (@Benzinga) May 4, 2022